## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## **EXPRESS MAIL CERTIFICATE**

Box Patent Application Hon. Commissioner of Patents and Trademarks Washington, DC 20231

Re: U.S. Patent Application for "GLP-2 Derivatives"

Applicants: Knudsen et al.

Sir:

Express Mail Label No. EM322113342US

Date of Deposit September 2, 1997

I hereby certify that the following attached paper(s) or fee

- 1. Application Fee Transmittal (in duplicate)
- 2. Patent Application
- 3. Unexecuted Combined Declaration and Power of Attorney
- 4. Preliminary Amendment

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.

Ann Quintero

(Name of person mailing paper(s) or fee)

(Signature of person mailing paper(s) or fee)

Mailing Address:

Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400 New York, NY 10017 (212) 867-0123



Attorney Docket No.:

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE APPLICATION FEE TRANSMITTAL

Box Patent Application Hon. Commissioner of Patents and Trademarks Washington, DC 20231

Sir:

Transmitted herewith for filing is the patent application of

Applicant(s):

Title:

22 pages of specification <u>0</u> sheets of drawings

2 sheets of Declaration and Power of Attorney

[x] The filing fee is calculated as follows:

Basic Fee: \$770.00

Total Claims:  $35 - 20 = 15 \times 22 = $330.00$ 

Independent Claims:  $1 - 3 = 0 \times 80 =$  \$ 0

Total Fee: \$1100.00

- [x] Priority of application serial nos. 0931/96 filed August 30, 1996 in Denmark and 1259/96 filed November 8, 1996 in Denmark are claimed under 35 U.S.C. 119. Certified copies will follow.
- [x] The benefit of application serial nos. 60/035,905 filed on January 24, 1997 and 60/036,226 filed on January 24, 1997 in the U.S. are claimed under 35 U.S.C. 120.
- [x] Please charge the required fee, estimated to be \$1100.00, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: September 2, 1997

Valeta A. Gregg, Reg. No. 35, 127 Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400

New York, NY 10174-6401

(212) 867-0123